Yaounde Central Hospital, NAtional Obesity Center
Yaoundé, Cameroon
NCT Number: NCT04222738
The aim of the study was the evaluation of cardiovascular benefits of Zingiber officinale Roscoe in patients with type 2 diabetes mellitus before and after 6 weeks of add-on therapy.
Looking for future studies?
Notify Me21 year–75 year
All sexes
Interventional
Phase 4
Yaoundé, Cameroon
the investigators performed a non-randomized single-arm clinical trial with a before and after design, carried out from December 2016 and May 2017.
Intervention consisted of the administration of powdered ginger extracts in the form of capsules at a dose of 2g/day, for a period of 6 weeks. Before and after intervention, the following were done by the participants: bioelectrical impedance analysis (BIA), blood pressure measurements, fasting blood sugar, HbA1c, lipid profiles, liver function tests, kidney function tests and full blood counts. These were followed by morphological workup including Electrocardiograms (ECGs), transthoracic heart ultrasounds and Ambulatory Blood Pressure Measurements (ABPM), also done before and after intervention.
Clinical evaluation with fasting blood sugar control and blood pressure controls were done at day 21 for safety purposes.
Healthy volunteers accepted: No
Only the study team can determine whether someone qualifies for participation.
Inclusion criteria
Exclusion criteria
The intervention lasted for six weeks and consisted of the administration of powdered ginger extracts in the form of capsules at a dose of 2g/day.
Time frame: 6 weeks
The mitral E' velocity is one of the methods for evaluating diastolic function.
Time frame: 6 weeks
E (early diastolic filling velocity)
Time frame: 6 weeks
Change in systolic and diastolic blood pressure by using ABPM (mmHg)
Time frame: 6 weeks
Change in weight (Kgs)
Time frame: 6 weeks
Change in HbA1c (%)
Time frame: 6 weeks
Change of triglycerides, LDL cholesterol, HDL cholesterol
Yaounde Central Hospital
Other Gov
Short Term Cardiovascular Effects of Zingiber Officinale as add-on Therapy in a Population of Type 2 Diabetes Individuals
Acronym: GINOFF1
OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.
View the official ClinicalTrials.gov record (opens in a new tab)This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.
Published trials that share one or more normalized conditions with this study.
NCT06406439
Diabetes (Insulin-requiring, Type 1 or Type 2), Diabetes Mellitus
Gwangmyeong, Deokan-ro, South Korea
View Trial DetailsNCT00038727
Body Weight, CVD
Rockville, Maryland, United States
View Trial DetailsNCT06029517
Arterial Occlusive Diseases, Arteriosclerosis
Buffalo, New York, United States
View Trial DetailsNCT01934660
Cardiovascular Disease, Cardiovascular Diseases
Bethesda, Maryland, United States
View Trial Details